Want to see CING full AI Analyst Report?
CING Stock Chart & Stats
$4.64
-$0.13(-2.91%)
At close: 4:00 PM EDT
$4.64
-$0.13(-2.91%)
Day’s Range― - ―
52-Week Range$3.16 - $11.89
Previous CloseN/A
Volume78.30K
Average Volume (3M)190.99K
Market Cap
$64.52M
Enterprise Value$10.24M
Total Cash (Recent Filing)$25.89M
Total Debt (Recent Filing)$7.43M
Price to Earnings (P/E)―
Beta5.01
Next Earnings
Aug 18, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.02
Shares Outstanding13,469,036
10 Day Avg. Volume270,731
30 Day Avg. Volume190,985
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.40
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.43
Forecast
1Y Price Target
$22.50Price Target Upside384.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.42
Revenue Forecast (FY)$3.63M
Bulls Say, Bears Say
Bulls Say
Patent ProtectionThe U.S. patent through December 2042 secures long-term exclusivity for CTx‑1301’s PTR formulation. Durable IP protection strengthens commercialization planning, increases partner/licensing leverage, and raises barriers to generic competition across the ADHD market horizon.
Platform Technology (PTR)Cingulate’s PTR platform is a structural competitive asset enabling timed dosing across CNS indications. Platform models support multiple assets with shared know-how, improving R&D efficiency, repeatable IP generation and partner appeal, creating durable upside beyond a single molecule.
Near-term Cash Runway For CMC WorkReported ~ $30M in cash earmarked for CMC remediation and resubmission reduces immediate financing pressure. That funding window allows the company to address material regulatory requirements and advance pre-commercial activities into 2027 without urgent recapitalization, supporting milestone execution.
Bears Say
No Revenue & Persistent LossesAs a development-stage biotech with no historical revenue and multi-year operating losses, Cingulate remains dependent on external financing and milestone outcomes. This structural revenue absence constrains strategic flexibility and increases dilution and execution risk until commercialization.
High Leverage / Balance Sheet RiskElevated debt-to-equity and a history of negative equity indicate a fragile capital structure. Higher leverage limits financial flexibility, increases refinancing and covenant risk, and magnifies consequences of clinical or regulatory delays, often forcing costly or dilutive financing choices.
FDA CMC Complete Response LetterA CRL centered on CMC is a structural regulatory hurdle: resolving manufacturing and controls issues can be time consuming, costly, and dependent on third-party partners. It materially delays approval and commercialization timelines and increases the probability of further regulatory requirements.
Cingulate Inc News
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $3.16 and its highest was $11.89 in the past 12 months.
What is Cingulate Inc’s market cap?
Cingulate Inc’s market cap is $64.52M.
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is Aug 18, 2026 which is in 10 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on May 14, 2026. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.52 by -$0.43.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -0.63.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 13,469,036 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.52. Following the earnings report the stock price went down -10.772%.
Which hedge fund is a major shareholder of Cingulate Inc?
Currently, no hedge funds are holding shares in CING
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cingulate Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (384.91% Upside)
$22.50 (384.91% Upside)
Hedge Fund Trend
Decreased
By 97.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $490.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
147.50%
Trailing 12-Months
Company Description
Cingulate Inc
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
CING Stock 12 Month Forecast
Average Price Target
$22.50
▲(384.91% Upside)
Technical Analysis
Medicinova
―
Clene
―
Pliant Therapeutics
―
Elicio Therapeutics
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
1.93% Insiders
2.80% Mutual Funds
0.31% Other Institutional Investors
90.64% Public Companies and
Individual Investors